Drugs / HT31-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07449572 | May → Nov 2026 expected | acute respiratory distress syndrome | HTIC, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HT31-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07449572 ↗ |
| Action | Inhibit | “HT31-1 injection is a first-in-class humanized monoclonal antibody that neutralizes citrullinated histone H3 (CitH3)” NCT07449572 ↗ |
| Modality | Monoclonal antibody | “HT31-1 injection is a first-in-class humanized monoclonal antibody” NCT07449572 ↗ |
| Route | Intravenous | “A single intravenous infusion of HT31-1 per cohort at ascending dose levels of 1 mg/kg, 5 mg/kg, and 20 mg/kg.” NCT07449572 ↗ |